Tandem Diabetes (NASDAQ: TNDM) holder to sell 131 RSU shares

Rhea-AI Filing Summary

Tandem Diabetes Care, Inc. (TNDM) received a notice under Rule 144 that Mark Novara intends to sell common stock through Morgan Stanley Smith Barney LLC. The filing lists a proposed sale of 131 shares of common stock on or about August 18, 2026 on NASDAQ.

The shares derive from restricted stock units, with the underlying securities noted as becoming available on August 15, 2026. The notice also reports prior 10b5-1 plan sales by Novara over the past three months.

Key Figures

Shares proposed for sale: 131 shares Proposed sale date: 08/18/2026 10b5-1 sale on June 17, 2026: 361 shares; $5,934.84 +2 more

5 metrics

Shares proposed for sale 131 shares Common stock to be sold through Morgan Stanley Smith Barney LLC around August 18, 2026

Proposed sale date 08/18/2026 Expected date of Rule 144 sale of Tandem Diabetes Care common stock on NASDAQ

10b5-1 sale on June 17, 2026 361 shares; $5,934.84 Common stock sold under a 10b5-1 plan for Mark Novara

10b5-1 sale on May 19, 2026 266 shares; $3,598.98 Common stock sold under a 10b5-1 plan for Mark Novara

RSU availability date 08/15/2026 Date tied to restricted stock units underlying the 131 shares to be sold

Key Terms

Rule 144, Restricted Stock Units, 10b5-1

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Units financial

"Common | 08/15/2026 | Restricted Stock Units | Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

10b5-1 regulatory

"10b5-1 Sales for MARK NOVARA 12400 High Bluff Drive"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

FAQ

What does the Rule 144 filing disclose for Tandem Diabetes Care (TNDM)?

The filing discloses that Mark Novara plans to sell 131 shares of Tandem Diabetes Care common stock under Rule 144, using Morgan Stanley Smith Barney LLC as broker, with sales expected around August 18, 2026 on NASDAQ.

How many Tandem Diabetes Care (TNDM) shares is Mark Novara proposing to sell?

Mark Novara is proposing to sell 131 shares of Tandem Diabetes Care common stock. These shares are linked to restricted stock units that become available on August 15, 2026, and are planned for sale around August 18, 2026.

Which broker is handling the planned TNDM stock sale under Rule 144?

The planned Tandem Diabetes Care (TNDM) stock sale is to be handled by Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, with execution on NASDAQ as disclosed in the Rule 144 notice.

What prior 10b5-1 plan sales of TNDM stock did Mark Novara report?

Mark Novara reported 10b5-1 plan sales of Tandem Diabetes Care (TNDM) common stock: 361 shares on June 17, 2026 for $5,934.84 and 266 shares on May 19, 2026 for $3,598.98, as shown in the three-month sales history.

What is the origin of the TNDM shares listed in this Rule 144 notice?

The planned sale of 131 TNDM shares is tied to restricted stock units issued by Tandem Diabetes Care, Inc. The securities are shown as becoming available on August 15, 2026, before the expected sale date of August 18, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 04:24 PM Accepted by SEC EDGAR 08/18/2026 - 04:23 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002000342
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Tandem Diabetes Care, Inc.
SEC File Number	001-36189
Address of Issuer	12400 High Bluff Drive San Diego CALIFORNIA 92130
Phone	8583666900
Name of Person for Whose Account the Securities are To Be Sold	MARK NOVARA
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	131	2915.41	69578707	08/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2026	Restricted Stock Units	Issuer			131	08/15/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for MARK NOVARA 12400 High Bluff Drive San Diego CA 92130	Common	06/17/2026	361	5934.84
10b5-1 Sales for MARK NOVARA 12400 High Bluff Drive San Diego CA 92130	Common	05/19/2026	266	3598.98

144: Remarks and Signature

Remarks
Date of Notice	08/18/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/04/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Mark Novara
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)